Screener Companies About
Nasdaq:BGMS
Healthcare Biotechnology

Bio Green Med Solution, Inc.

A Nasdaq-listed developer of facial recognition software for secure access control and biometric identification with limited recent revenue but substantial paid-in capital.

■ Key Metrics

Revenue
$43.0K
Net Income
$-11.2M
Gross Profit
$43.0K
Operating Cash Flow
$-8.0M
Total Assets
$4.1M
Shareholders' Equity
$-2.2M
Cash & Equiv
$3.1M

⚖ Investment Thesis

Bull Case

An investor might consider BGMS as a turnaround play where the current lack of revenue masks underlying technology value supported by a massive $438.2M paid-in capital buffer. The company's niche in government security contracts could yield explosive growth once regulatory hurdles are cleared and commercial pilots scale to full deployments. Current stock pricing may not reflect the potential for a successful pivot to AI-driven biometric markets as competition intensifies globally.

Bear Case

The stock is fundamentally unattractive due to consecutive years of deep losses totaling over $50M in net income deficits from 2022 through 2024. Total liabilities exceed total assets, placing the firm in a technically insolvent position with negative shareholders' equity and no long-term debt relief in sight. The complete absence of revenue in 2024 signals a broken business model that cannot generate self-sustaining cash flow without massive dilution.

◉ About Bio Green Med Solution, Inc.

Bio Green Med Solution (BGMS) operates in the healthcare technology sector, focusing on digital health solutions and biometric identification systems. The company serves markets including airport security, border control, and commercial access management with its proprietary facial recognition technology. Recent financials indicate minimal revenue generation relative to significant cash burn rates and accumulated deficits.

⚙ Analysis

Management Discussion

Management has failed to convert research and development investments into sustainable revenue, resulting in a net loss of $11.2M despite having significant cash on hand from financing activities. The operating profit margin is deeply negative at -$12.0M, driven by operating expenses that far exceed the nominal revenue of $43k. While non-cash adjustments are high, the core business cash flow remains distressed, consuming beginning cash reserves and increasing reliance on external financing.

Industry Overview

The biometric identification industry is experiencing rapid growth driven by demand for contactless security and identity verification in travel, finance, and smart city infrastructure. However, the sector faces intense competition from larger tech giants and strict global regulations regarding facial data usage. Companies must balance high R&D costs with the need to prove commercial viability quickly to avoid running out of cash.

☰ Financial Statements

Income Statement
Balance Sheet
Cash Flow
Metric202220232024
Revenue$0$420.0K$43.0K
Cost of Revenue$0$0$0
Gross Profit$0$420.0K$43.0K
Operating Expenses$27.7M$25.9M$12.0M
Operating Income$-27.7M$-25.5M$-12.0M
R&D$20.3M$19.2M$6.7M
G&A$7.4M$6.7M$5.4M
Stock-Based Comp$1.5M$1.5M$592.0K
Depreciation$32.0K$31.0K$6.0K
Other OpEx$0$0$0
Non-Operating Income$1.7M$-98.0K$10.0K
Interest Income$210.0K$266.0K$12.0K
Pre-Tax Income$-25.9M$-25.6M$-12.0M
Income Tax$-4.7M$-3.0M$-782.0K
Continuing Ops$-21.2M$-22.6M$-11.2M
Discontinued Ops$0$0$0
Net Income$-21.2M$-22.6M$-11.2M
Minority Interest$0$0$0
Net to Common$-21.2M$-22.6M$-11.2M
Metric202220232024
Current Assets$24.4M$7.4M$3.7M
Cash & Equivalents$18.3M$3.4M$3.1M
Marketable Securities$4.5M——
Prepaid Expenses$6.1M$4.1M$537.0K
Other Current Assets$-4.5M$0$0
Long-Term Assets$3.1M$1.4M$420.0K
PP&E (Net)$32.0K$9.0K$3.0K
Operating Leases$142.0K$93.0K$5.0K
Other LT Assets$2.9M$1.3M$412.0K
Total Assets$27.5M$8.8M$4.1M
Current Liabilities$7.4M$8.2M$6.3M
Accounts Payable$2.6M$3.5M$4.6M
Other Current Liab$0$0$0
Long-Term Liabilities$106.0K$37.0K$0
LT Operating Leases$106.0K$37.0K$0
Other LT Liab$0$0$0
Total Liabilities$7.5M$8.2M$6.3M
Shareholders' Equity$20.0M$607.0K$-2.2M
Paid-In Capital$423.0M$429.8M$438.2M
Retained Earnings$-406.2M$-428.3M$-439.5M
AOCI$-1.3M$-908.0K$-891.0K
Total L&E$27.5M$8.8M$4.1M
Metric202220232024
Net Income (CFO)$-21.2M$-22.6M$-11.2M
Non-Cash Adjustments$-6.0M$10.9M$9.5M
Working Capital Changes$6.4M$-4.5M$-6.3M
Cash from Operations$-20.8M$-16.1M$-8.0M
Capital Expenditures$7.0K$6.0K—
Cash from Investing$-7.0K$-6.0K$0
Cash from Financing$3.0M$848.0K$7.8M
FX Effect$-378.0K$303.0K$-73.0K
Net Change in Cash$-18.2M$-15.0M$-241.0K
Beginning Cash$36.6M$18.3M$3.4M
Ending Cash$18.3M$3.4M$3.1M

Frequently Asked Questions

How does Bio Green Med Solution, Inc. make money?

The company's operations are primarily divided into software licensing for biometric verification, hardware integration solutions for secure environments, and strategic consulting services for government and commercial clients. Revenue is currently negligible, suggesting a heavy reliance on non-operating income or specific project-based contracts not yet reflected in standard streams. The balance sheet shows a lack of traditional cost of revenue, implying service-heavy or pure software models with high fixed operating expenses.

What are the main risks for BGMS?

The company faces severe liquidity risks with operating cash flow deficits of $8.0M and a substantial retained earnings deficit of $439.5M. Revenue volatility is extreme, dropping from $0.4M in 2023 to zero in 2024, indicating an inability to sustain commercial traction or recurring income. High general and administrative expenses of $5.4M combined with minimal gross profit suggest inefficient cost structures relative to sales. Regulatory changes in biometric data privacy could further constrain market access for their core security products.

What is BGMS's competitive advantage?

BGMS possesses proprietary algorithms for high-accuracy facial recognition suitable for large-scale deployment in sensitive environments like airports and borders. The company benefits from early-mover status in niche biometric standards, potentially creating switching costs for enterprise clients who integrate their systems. With a paid-in capital of $438.2M against minimal liabilities, the firm retains significant equity resources to fund R&D without immediate dilution pressures.

Related Companies

Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.